Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.9% Following Insider Selling

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares dropped 4.9% during mid-day trading on Tuesday following insider selling activity. The company traded as low as $18.61 and last traded at $18.73. Approximately 40,658 shares were traded during trading, a decline of 85% from the average daily volume of 275,231 shares. The stock had previously closed at $19.68.

Specifically, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total value of $69,322.50. Following the transaction, the chief financial officer now owns 23,000 shares in the company, valued at approximately $490,590. This represents a 12.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Analyst Upgrades and Downgrades

ELVN has been the topic of a number of recent research reports. HC Wainwright increased their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, March 21st. BTIG Research assumed coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 price objective on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics presently has an average rating of “Buy” and an average price target of $38.75.

Enliven Therapeutics Stock Down 5.0 %

The firm has a 50 day moving average price of $21.24 and a 200 day moving average price of $23.72. The stock has a market capitalization of $916.23 million, a PE ratio of -9.85 and a beta of 1.04.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million for the quarter. On average, equities analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. boosted its stake in shares of Enliven Therapeutics by 3.5% in the 4th quarter. Invesco Ltd. now owns 15,072 shares of the company’s stock worth $339,000 after buying an additional 508 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Enliven Therapeutics by 3.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company’s stock worth $451,000 after purchasing an additional 718 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Enliven Therapeutics by 14.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock valued at $233,000 after purchasing an additional 1,275 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in shares of Enliven Therapeutics by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 21,746 shares of the company’s stock worth $489,000 after buying an additional 1,285 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.